Recent Updates — REGN

Regeneron Pharmaceuticals reported third-quarter 2026 total revenues of $5.1 billion, a 36% increase from the prior year period. GAAP diluted EPS rose 35% to $18.45, while non-GAAP diluted EPS increased 70% to $20.07. The company declared a quarterly cash dividend of $0.94 per share, payable on December 3, 2026, to shareholders of record as of November 20, 2026. Additionally, Regeneron expanded its collaboration with Sanofi, receiving a $1.0 billion up-front payment for next-generation immunology antibodies. The biotechnology company invents, develops, and commercializes life-transforming medicines for serious diseases.

Regeneron Pharmaceuticals entered into a Sixth Amendment to its Amended and Restated License and Collaboration Agreement with Sanofi. The deal establishes a co-development and co-commercialization partnership for four new long-acting antibodies targeting IL-13, IL-4, IL-4Rα, and IL-4xIL-13. Sanofi will pay an upfront fee of $1.0 billion to Regeneron, with potential additional payments of up to $7.0 billion upon achievement of development, regulatory, and commercial milestones. Profits from the new products will be shared equally between the parties. Concurrently, Regeneron agreed to dismiss its lawsuit against Sanofi regarding audit rights and information access for Dupixent. The filing also notes an expected acquired in-process research and development charge of approximately $22 million for the third quarter 2026. Regeneron is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases.

Regeneron Pharmaceuticals granted one-time performance share unit (PSU) awards to CEO Leonard S. Schleifer and CSO George D. Yancopoulos, replacing annual equity grants through 2036. The ten-year performance period ends December 31, 2035, with a mandatory holding period until February 2036. Maximum earnouts are capped at 2,700,000 PSUs for the CEO and 2,900,000 for the CSO. Payouts depend on new product filings, approvals, and generating up to $30 billion in annual revenues from new products, adjusted by a relative TSR modifier against the NASDAQ Biotechnology Index. The company also formed a nominal-value subsidiary for potential non-core opportunities, granting equity stakes to both executives. Regeneron Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing medicines.

Regeneron Pharmaceuticals reported second quarter 2026 total revenues of $4.3 billion, a 17% increase year-over-year, driven by strong commercial performance. Global net sales of Dupixent reached a record $6.0 billion (up 38%), while U.S. EYLEA HD sales rose 52% to $596 million and global Libtayo sales increased 30% to $489 million. GAAP diluted EPS was $12.23, including a $1.02 negative impact from in-process research and development (IPR&D); non-GAAP diluted EPS was $14.29. The company fully repaid the Sanofi Development Balance by the end of the quarter. Regulatory submissions for cemdisiran were accepted for review by the FDA and EMA, with a target FDA action date in November 2026. Additionally, Regeneron declared a quarterly cash dividend of $0.94 per share, payable on August 31, 2026 to shareholders of record as of August 18, 2026. The company operates in the biotechnology industry, inventing and commercializing medicines for serious diseases.

Regeneron Pharmaceuticals, Inc. expects an acquired in-process research and development charge of approximately $127 million on a pre-tax basis for the second quarter of 2026. This charge, related to collaboration and licensing agreements, is expected to negatively impact GAAP and non-GAAP net income per diluted share by approximately $1.00. Regeneron is a biotechnology company that develops and manufactures biopharmaceutical products.